Background: Vorinostat combined with retinoids produces additive antitumor effects in preclinical studies of neuroblastoma. Higher systemic exposures of vorinostat than achieved in pediatric phase I trials with continuous daily dosing are necessary for in vivo increased histone acetylation and cytotoxic activity. We conducted a phase I trial in children with relapsed/refractory neuroblastoma to determine the maximum tolerated dose (MTD) of vorinostat on an interrupted schedule, escalating beyond the previously identified pediatric MTD.
toxicities. A total of 18 patients experienced grade 3/4 toxicities related to study therapy. The maximum intended dose of vorinostat (430 mg/m 2 /day, days 1-4; 8-11) was tolerable and led to increased histone acetylation in surrogate tissues when compared to lower doses of vorinostat (P = 0.009). No objective responses were seen.
Conclusions:
Increased dose vorinostat (430 mg/m 2 /day) on an interrupted schedule is tolerable in combination with isotretinoin. This dose led to increased vorinostat exposures and demonstrated increased histone acetylation. Prolonged stable disease in patients with minimal residual disease warrants further investigation.
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INTRODUCTION
Neuroblastoma, a neoplasm of the sympathetic nervous system, is the most common solid tumor of early childhood. Clinical and tumor biologic factors ascertained at diagnosis of neuroblastoma identify those children who are at risk for poor long-term outcome despite intensive multimodal therapy (defined as high-risk neuroblastoma), and outcome for high-risk patients who fail to respond to or relapse after upfront therapy remains poor. 1 In a phase III randomized trial, administration of isotretinoin (cis-13-retinoic acid) at 80 mg/m 2 /dose administered twice daily for 2 weeks monthly over a period of 6 months following consolidation therapy improved 3-year event-free survival from 29% in the control cohort to 45% in patients receiving isotretinoin. 2, 3 Isotretinoin is therefore a standard agent for high-risk neuroblastoma.
Novel therapies that enhance the efficacy of isotretinoin may lead to further improvement in survival for patients with this disease.
Deregulation of histone acetylation (HA) has been implicated in the development of a range of malignancies. Thus, there is considerable interest in the use of inhibitors of histone deacetylases (HDAC) as a potential therapeutic modality in the treatment of hematological and solid tumor malignancies. 4 Inhibitors of HDACs may relieve transcriptional repression caused by the products of certain oncogenes, leading to gene reactivation of tumor suppressors or death pathway genes, which have been abnormally silenced in the generation of the malignant phenotype. This reactivation may lead to cell cycle arrest, induction of apoptosis, differentiation, or autophagy. 5 Neuroblastoma is thought to arise from defects in neural crest differentiation caused by aberrant gene regulation. Thus, compounds that affect chromatin structure, such as HDAC inhibitors, are potentially useful agents for the treatment of neuroblastoma.
Retinoic acid receptors (RARs) function as modulators of transcription through the recruitment of coregulator complexes. In the absence of a ligand, RARs recruit corepressor (CoR) complexes with HDAC activity, resulting in histone deacetylation, chromatin compaction, and subsequent repression of gene transcription. In contrast, RAR agonist binding causes a conformational change that destabilizes the binding of CoR and creates a new interaction surface that recruits co-activator complexes with histone acetyltransferase activity, leading to increased HA, local chromatin decondensation, and transcriptional activation. 6 The antitumor activity of retinoic acids (RAs) are thought to be derived from their ability to induce differentiation and/or apoptosis of cancer cells. These findings have led to considerable interest in combining an HDAC inhibitor with a retinoid (such as isotretinoin) for synergistic activity in the treatment of hematological and solid malignancies. this vorinostat dose may be insufficient to result in HDAC inhibition. 11 Based on the lack of PBMC HA observed on the COG trial, the New Approaches to Neuroblastoma Therapy (NANT) Consortium sought to explore an alternative vorinostat schedule. Adult clinical trials support the feasibility of delivering higher daily doses of vorinostat given for shorter durations compared to standard dosing of 400 mg once daily continuously. [12] [13] [14] [15] Based on these observations, a phase I trial was designed to assess whether an interrupted schedule of escalating doses of vorinostat (dosed on days 1-4 and 8-11 of every 28-day cycle) would allow a higher MTD in combination with standard-dose isotretinoin and would lead to improved HA.
METHODS

Patients
Patients were required to meet standard NANT eligibility criteria (outlined in Supplementary Material S1). Once the MTD of vorinostat was determined, an expansion cohort was opened at this dose level in order to further characterize the pharmacokinetic (PK) and pharmacodynamic profiles of the intermittent vorinostat dosing regimen. This cohort sought to enroll an additional six patients. Eligibility criteria for the expansion cohort were modified to also allow patients who had entered a second complete remission after relapse to enroll with no evidence of disease. Patients with measurable/evaluable disease were also allowed to enroll on the expansion cohort, with the same eligibility requirements outlined in Supplementary Material S1.
All patients were required to meet standard organ function criteria before enrolling (outlined in Supplementary Material S1).
Patients were excluded if they were pregnant, breastfeeding, or 
Protocol therapy
Patients received fixed doses of isotretinoin at 80 mg/m 2 /dose (2.67 mg/kg/dose for patients < 12 kg) given twice daily for the first 14 days of each 28-day cycle. Vorinostat was administered once daily on days 1-4 and days 8-11 of each 28-day cycle. The starting vorinostat dose was 180 mg/m 2 /dose; planned subsequent doses 230, 300, 360, and 430 mg/m 2 /dose (maximum absolute dose capped at 800 mg).
In the absence of clinical/radiographic or bone marrow evidence of progression, patients could continue to receive up to 24 cycles of therapy (effective with Amendment 9, previously 12 cycles) as long as the patient did not have tumor progression and met laboratory and clinical parameters prior to the start of each cycle of protocol therapy. Patients who met the criteria for permanent discontinuation of vorinostat due to toxicity were removed from protocol therapy.
Toxicity assessment
Toxicity was assessed and reported for all patients who began vorinostat therapy using the Common Terminology Criteria for Adverse Events criteria, version 4.0. Patients who, during the first cycle,
(1) received less than 75% of the planned doses of vorinostat for reasons other than toxicity and (2) did not experience a dose-limiting toxicity (DLT) were replaced for the purposes of evaluating the dose level for dose escalation/de-escalation decisions (that is, not evaluable for DLT). DLT was defined as events that were possibly, probably, or definitely attributable to the combination of vorinostat and isotretinoin. Hematologic DLT was defined as grade 4 thrombocytopenia (platelet count < 25,000/mm 3 ) or neutropenia (absolute neutrophil count < 500/mm 3 ) resulting in delays of greater than 7 days in protocol directed therapy, grade 4 thrombocytopenia requiring one or more platelet transfusions, or any adverse event requiring omission of three or more doses of vorinostat. Patients with known bone marrow metastatic disease were eligible for study but were not evaluable for hematologic toxicity. Additional DLT criteria are outlined in Supplementary Material S1.
Response evaluation
Patients underwent disease evaluation at baseline, after cycles 2 and 4, and then every three cycles. Overall response was graded according to the NANT Response Criteria (v1.0), as previously described. 16 Overall responses of complete response (CR) or partial response (PR)
were considered objective responses. Patients were considered evaluable for response if they received at least 75 percent of vorinostat in one course or experienced a DLT at any time after at least one dose of vorinostat. Patients who had progressive disease were considered to be evaluable for response regardless of drug administration.
Local radiographic (anatomical imaging and methyliodobenzylguanidine [MIBG]) and bone marrow reports (aspirates and biopsies)
were centrally reviewed at NANT Operations Center for accuracy so they were consistent with assigned overall response after any queries were resolved. MIBG scans from baseline were centrally reviewed for all patients to accurately and consistently describe MIBG avid disease at study entry.
PK and pharmacodynamic studies
All patients were required to submit serial samples during cycle 1 for vorinostat PK studies. Three ml of blood were drawn into a serum separator tube before the first dose of vorinostat on day 1 and then at hours 0.5, 1, 1.5, 2, 4, 6, 8, and 24 (before the vorinostat dose on day 2). Samples were processed and batch analyzed as previously described. 17 For optional isotretinoin PK studies, 5 ml of blood were collected into sodium heparin tubes 4 hr after the last morning dose of isotretinoin during cycle 1 (day 14). Samples were processed and batch analyzed as previously described. 18 The study included an optional vorinostat pharmacodynamics aim to correlate PBMC HA with vorinostat PKs. 5 mL of blood were collected in a sodium heparin tube at four time points: cycle 1, day 1 predose, and at 1, 6, and 24 hr post the first dose. ELISA was used to quantify acetylated histone H3 as previously described. 19 
Study design and statistical methods
Evaluation of vorinostat dose levels followed the 3 + 3 dose escalation design. 20 Dose escalation considerations were based on cycle 1 data only. The MTD was the highest dose level tested at which 0/6 or 1/6 patients experienced DLT with at least 2/3 or 2/6 patients encountering DLT at the next higher dose. Once the MTD was determined, an expansion cohort was opened at that dose level in order to further characterize the PK and pharmacodynamic profiles of the intermittent vorinostat dosing regimen.
Progression-free survival (PFS) was calculated as time from start of treatment to first episode of disease progression or death from any cause, whichever was observed first; patients who were alive and without progression were censored at last follow-up. For one patient who withdrew from treatment and died 2 months later, with date of progression unknown, the date of progression was taken as 1 month after withdrawal from treatment. Kaplan-Meier plots were used to summarize PFS and overall survival (OS).
For vorinostat PK measurements, geometric means and associated 95% confidence intervals were calculated; for isotretinoin PK measurements, because of the limited numbers of values, medians and ranges are presented. For each patient, at each time point, the HA color intensity values were measured in triplicate; observed color intensity values were log-transformed and the averages of the three readings were calculated. In addition, for each patient, the baseline average HA value was subtracted from the average HA value at 1, 6, and 12 hr. For presentation, the HA differences (and means and associated 95% confidence intervals) were transformed back into percent change. In a final analysis to explore associations, the maximum percent change in HA was determined for each patient. To obtain a quantitative assessment of the associations between vorinostat and isotretinoin PK's, and dose level and percent change in HA levels, the Pearson correlation was calculated; for all other associations, the Spearman correlation was calculated. Scatterplots were drawn and inspected whenever possible. To evaluate the association between HA levels (the averages and the differences from baseline) over time and over the dose levels, a generalized linear model was used with patient as a random effect and dose level and time as fixed effects. All P-values are two-sided.
RESULTS
Patient characteristics
Twenty-nine patients enrolled from January 2011 through October 2013. No patients were determined to be ineligible after enrollment.
Characteristics of the 29 eligible patients are provided in Table 1. One patient on dose level 1 missed three doses of vorinostat (due to concurrent infection) and was deemed inevaluable for dose escalation decisions and was replaced. Ten patients were inevaluable for response. Reasons for inevaluability included taking less than 75% of prescribed protocol therapy and withdrawal from protocol therapy (n = 2), incomplete restaging evaluation (n = 1), off treatment due to unacceptable toxicity and disease evaluation was not completed (n = 1), and entering protocol therapy in a CR with no evaluable disease in the expansion cohort (n = 6). Twenty-three patients were previously exposed to isotretinoin and two patients were previously exposed to vorinostat. 
TA B L E 1 Patient demographics
Patient and disease characteristics (n = 29)
Number of patients (%)
Male
Dose escalation and toxicity
A summary of the dose escalation is provided in Table 2 Table 3 .
Vorinostat/isotretinoin PKs
Vorinostat and isotretinoin PK were collected during cycle 1 of therapy. A total of 28 patients provided samples for vorinostat PK; 23 provided all required specimens. Table 4 summarizes the vorinostat PK results.
The mean apparent oral vorinostat clearance was 151 l/hr (range 58-435 l/hr) on the interrupted dosing schedule. Vorinostat clearance and half-life (2.8 hr, range, 1.2-10.1 hr) appeared stable across dose levels, consistent with linear PK (P = 0.60 and P = 0.39, respectively).
There was substantial interpatient variability in SAHA maximum concentration (mean 428 ng/ml, range 158-980 ng/ml) and area under the curve (AUC) (median 2174 ng/ml/hr, range 930-5776 ng/ml/hr) values across dose levels, and both increased with dose (P < 0.001 and P = 0.003, respectively).
An optional single isotretinoin PK sample was drawn 4 hr after the last dose of isotretinoin in cycle 1 in 12 out of 29 patients. The isotretinoin median serum concentration was 0.83 g/ml (range 0.19-1.40 g/ml) and the 4-oxo-13-cisRA median serum concentration was 3.17 g/ml (range 0.47-5.84 g/ml). There was no apparent association between vorinostat dose and either the RA or the 4-oxo-13-cisRA serum levels (P = 0.68 and P = 0.39, respectively), nor any association with the vorinostat PK levels.
Vorinostat pharmacodynamics
Twenty-three of 29 patients consented to the optional vorinostat pharmacodynamic assessments. Fifty-three adequate PBMC samples were obtained from 16 patients (nine treated at dose levels 1-4 and seven treated at dose level 5/expansion cohort). Overall, the percent change from baseline in HA levels at 1 hr post treatment was significantly greater in dose level 5 compared to dose levels 1-4 (P = 0.009) and this difference persisted at hours 6 and 24 (Table 5) . After controlling for the dose level, there was an association between the vorinostat AUC and clearance values and the increase in HA levels (P = 0.021 for both AUC and clearance).
Antitumor activity
No objective responses were seen on this study. A median of two cycles were administered (range 1-15). Eleven (38%) of the 29 patients completed ≥4 (median 11, range 4-15) cycles without tumor progression.
Nineteen patients were evaluable for full response assessment; six patients were in CR at study entry and four were classified as inevaluable for response (one patient received only 50% of prescribed therapy and three were not re-evaluated after start of treatment). Of those 
DISCUSSION
The administration of isotretinoin in the setting of minimal residual disease has improved outcomes for children with high-risk neuroblastoma and is considered standard-of-care as a component of postconsolidation maintenance therapy. Preclinical data suggest that the HDAC inhibitor vorinostat has modest single-agent activity in neuroblastoma xenograft experiments, 10 and may have additive antitumor effects when combined with retinoids. [7] [8] [9] We demonstrate that an interrupted schedule of higher dose vorinostat can be safely combined with standard doses of isotretinoin in children with high-risk neuroblastoma, achieving in vivo pharmacodynamic activity as determined by PBMC HA without excess toxicity.
Preclinical studies suggest that a higher systemic exposure to vorinostat may be necessary to achieve maximal antitumor activity. 10 In a previous pediatric phase I trial, single agent MTD of vorinostat The percent changes in HA levels were greater in the dose level 5 cohort (P = 0.009 for the main effect of cohort). For both cohorts, the changes were not different at the three different time points (P = 0.76 for the main effect of hour).
cycles of therapy. In addition, 83% (5/6) of patients who entered with no evidence of disease were able to complete four or more cycles without disease progression. Given the favorable prolonged SD rate, 
